生物制药公司Scholar Rock Holding Corp（SRRK）今日盘前股价大幅上涨5.8%，引起了市场关注。
消息面上，公司在其发布的财报中表示，计划重新提交其实验性药物apitegromab的上市申请，该药物用于治疗脊髓性肌萎缩症（SMA）。此举是在与美国食品药品监督管理局（FDA）及相关生产工厂会面后做出的，监管机构认为无需采取进一步行动。此前，该药物因生产工厂的问题未获批准。
Apitegromab是Scholar Rock推动公司增长和盈利能力的关键产品，目前还在进行针对肥胖症肌肉保存的临床试验。市场将此视为公司研发管线的重要积极进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.